Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Atractylenolide I
Cat. No.:
0225LY-0967
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Atractylenolide-I exerts anti-inflammatory effects by lowering IL-6 and TNF-α levels to improve organ function in sepsis; it also increases the sensitivity of EOC cells to paclitaxel by disrupting TLR4/MyD88 signaling.
Synonym:
73069-13-3; Atractylenolide-1; AtractylenolideI; Atractylenolide 1; Atractylenolide-I; (4aS,8aS)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4H-benzo[f][1]benzofuran-2-one; MFCD09037395; (4aS,8aS)-3,8a-dimethyl-5-methylene-4a,5,6,7,8,8a-hexahydronaphtho[2,3-b]furan-2(4H)-one
CAS No.:
73069-13-3
Compound CID:
5321018
Formula:
C15H18O2
Formula Weight:
230.3
Specification
Relative Density:
1.12 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Atractylenolide I can be used in pharmacology research to evaluate its anti-inflammatory and gastroprotective biological activities.
Library Information
Target:
TLR; IL receptor; JAK; STAT; TNF
Receptor:
IL-6; JAK; STAT; TLR; TNF-α
Pathways:
JAK/STAT signaling; Immunology/Inflammation; Apoptosis; Tyrosine kinase/adaptors; Stem cell regulation
Plate Number:
AOCL-13
Plate Location:
d8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55.00 mg/mL; 238.82 mM
